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Objectives: Outcomes-based pricing and reimbursement arrangements (OPRAs), 
a type of performance-based risk-sharing (PBRS) arrangements, have emerged as a 
promising avenue for payers to share pharmaceutical risk and for manufacturers to 
improve access. The aim of this study was to explore the U.S. and EU-5 perspectives 
regarding historical and future activity for OPRAs as well as payers’ and manufactur-
ers’ perceptions of OPRAs. MethOds: Our study combined 2 approaches: targeted 
literature review and primary research with U.S. and EU-5 stakeholders. The targeted 
literature review included the following sources: University of Washington’s PBRS 
Database, payer and health technology assessment agencies’ websites, Factiva, 
PubMed, and congress abstracts. Only schemes relating to pharmaceuticals were 
included. Twenty-seven experts were interviewed using a structured questionnaire: 
14 US payers, 5 EU-5 national payers, 8 manufacturers’ pricing/market access execu-
tives (4 US, 4 EU-5). Results: A total of 117 arrangements were identified from 
1994 to 2014. This understates the level of OPRA activity as many schemes are 
confidential. U.S. and EU-5 interviewees expect that 2 to 10 times more OPRAs 
will be implemented in the next 5 years than in the previous 5 years. Historically, 
Italy has accounted for most OPRA activity; however, other nations are expected 
to increase OPRA activity. Key drivers include the introduction of a national OPRA 
framework in Spain, potentially a similar framework in the United Kingdom, a grow-
ing sick-fund activity in Germany, and a US movement towards accountable care. 
Motivation for OPRAs varies markedly across markets and stakeholders, with opera-
tional feasibility a significant hurdle in the U.S. and France. Cost and risk reduction 
were the primary focus for payers, while improving access was key for manufactur-
ers. cOnclusiOns: This research suggests high OPRA growth is expected in the 
EU-5 and, to a lesser extent in the U.S., particularly if clear, uncomplicated OPRA 
frameworks can be developed.
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Objectives: Pharmaceutical risk-sharing agreements are a type of contract 
between drug manufacturers and third party payers. These agreements are increas-
ingly being used as part of formulary listing decisions due to uncertainties about 
price and performance of new drugs at the time of launch. We develop a game 
theoretic model of a pay-for-performance agreement. MethOds: We model inter-
actions between the payer and manufacturer as a Stackelberg game. The pharma-
ceutical firm chooses the drug price and then the payer chooses which patients 
will be eligible for treatment. Following treatment the manufacturer pays a rebate 
to the payer for all patients who did not respond to the new drug. We solve for the 
optimal price and treatment decisions by both parties. We define the social welfare 
as the sum of the payer’s and manufacturer’s objective functions, and investigate 
whether a combination of taxes, subsidies and additional rebates can result in the 
optimal social welfare when the two parties act independently in a decentralized 
system. Results: We examine how the rebate rate determines the payer’s optimal 
treatment decisions. Specifically, we find a break-even threshold for the rebate rate 
for which the payer incurs neither a loss nor gain for patients not responding to the 
drug. We create several numerical examples to investigate how the distribution of 
the probability of success throughout the population influences the manufacturer’s 
profits and the net health benefits purchased by the payer. We find that a single 
rebate based on performance does not, in general, lead to a socially optimal out-
come, but that that socially optimal outcome can be achieved through additional 
rebates or by using appropriately designed taxes and subsidies. cOnclusiOns: A 
pay-for-performance risk-sharing agreement may be welfare-improving for certain 
ranges of rebate rate. Formulary managers should be aware of the incentives cre-
ated by different types of agreements when negotiating with drug manufacturers.
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Objectives: In August/2014 the Brazilian government opened for public consulta-
tion its bill on public-private partnerships (PDPs). The aim of this study is to under-
stand the current situation of the public-private partnership in Brazil. MethOds: 
We combined different database publicly available in the government website 
(www.saude.gov.br) encompassing: a) projects under analysis (submission period: 
March/2013-April/2014); b) products currently being purchased via PDPs; and c) 
projects rejected by the Ministry of Health. Results: There are 43 projects under 
analysis by the Ministry of Health, oncology representing over 50% of the submis-
sions. Government currently purchases 13 products from 7 official laboratories, vac-
cines being the main products. 151 projects were rejected by the Ministry of Health, 
participation of different therapeutic areas is fragmented. cOnclusiOns: To this 
point, data shows that vaccines are the key products in the PDP arena. However, 
according to recent submissions, oncology seems also to be a field of interest.
HEaltH carE usE & Policy studiEs – conceptual Papers
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Two-Part Pricing for Patent Protected Medicines – An Economic Analysis from a 
Swedish Health Care Perspective Holm, H J and Hertzman, PObjectives: Many new 
medicines are targeting small patient populations. In order to recoup R&D costs the 
medicines are highly priced. A dilemma is that the price per patient (or pill or vial) can 
Objectives: To asses and obtain data on the proper use of drugs and present irrational 
drug use pattern by medical practitioners that weather the patients receive the medi-
cines, weather these are appropriate for their clinical needs, in proper doses, for appro-
priate periods of time, weather cost effective and were dispensed properly. MethOds: 
This study was designed to asses’ irrational drug use pattern which is a great concern of 
the entire world and WHO in general and in our country in particular. For this study we 
used the WHO indicators utilizing the services of trainee Pharmacists in two major city 
Hospitals. This study was conducted from April, 15th 2014 to May, 14th 2014. Data was 
collected using patient’s prescriptions and direct patient communication using a struc-
tured check list for the prescribing indicators including number of drugs per prescription, 
number of antibiotics, number of injections, number of steroids and number of food sup-
plements. The patient care data, including proper doses, proper timing, cost effectiveness 
and proper dispensing was directly interpreted and analyzed over the dispensing coun-
ters of Pharmacies by the trainee Pharmacists. Results: The results showed that in both 
hospitals (860 prescriptions), the average number of drugs per prescription were 5, the 
patients were prescribed antibiotics at least two antibiotics per prescription (40%).The 
percentage of injections, steroids and food supplements were 20% each. The percentage 
of proper doses, proper timing, cost effectiveness and proper dispensing was 70%, 60%, 
20% and 20% respectively. This irrational prescribing pattern/habit of the medical practi-
tioners was observed in both the hospitals. cOnclusiOns: This study indicates that this 
type of irrational practice is the reflection of state and regulatory affairs in the country 
and this is a warning for all developing countries which need strict regulations and strat-
egies for drug prescriptions and dispensing including the utilization of services of more 
Pharmacists.
HEaltH carE usE & Policy studiEs – risk sharing/Performance-based  
agreements
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Objectives: Step therapy is defined as the practice of beginning drug therapy 
for a medical condition with the safest and most cost-effective drug therapy and 
progressing to more risky or costly therapies. This analysis assessed the number 
of US health plans that require patients to step through a branded boxed warning 
product before initiating a branded non-boxed warning product. MethOds: This 
cross-sectional analysis was conducted using formulary data compiled by the MMIT 
Formulary Analytics Specialty Assessment database, which includes 2015 formulary 
status and policies for all US health plans. Of the 27 therapeutic classes that include 
products with a boxed warning, 9 therapeutic classes met all of the following criteria: 
(1) include currently marketed branded products, (2) include branded boxed warning 
products, (3) include branded non-boxed warning products, (4) include specialty or 
small-molecule products. Formulary requirements and restrictions for the 30 largest 
commercial US health plans were examined for cases in which patients are required 
by formulary design to step through a branded drug with a boxed warning before 
initiating a product without a boxed warning. Results: The 30 commercial plans 
represented 121 million lives, or 56% of the 217 million commercial lives in the United 
States. The number of health plans requiring patients to step through a branded 
boxed warning drug before initiating a non-boxed warning product in the 9 thera-
peutic classes included were: anti-infectives (miscellaneous), 0; anticonvulsants, 0; 
antidiabetics, 0; gastrointestinal agents, 0; immunological agents and biologics, 18 
(45% of covered lives); respiratory agents, 0; dermatologic agents, 0; central nervous 
system drugs (anti-Parkinson), 0; and renal agents, 0. cOnclusiOns: The designs of 
US formularies generally do not require a step through products with a box warning 
prior to initiating a product without a boxed warning. The one notable exception is 
the class of immunological agents and biologics.
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Objectives: To identify the key milestones for the public-private partner-
ships in Brazil. MethOds: We conducted a literature review (2004-2014) on the 
legislation and local articles about public-private partnership (PPP) for drugs in 
Brazil. Results: In 2004 the government issued law #11079 establishing general 
rules for PPPs in all sectors. The first specific mention to healthcare was done in 
the article ‘Development, health-industrial complex and industrial policy’ (Gadelha, 
2006). In 2010 via the decree #1284 the government sets its list with the strategic 
products for the healthcare public system. Still in 2010 law #12349 creates the prefer-
ence margin benefiting in bids/tenders products locally produced. In 2013 in “Brasil 
Maior” plan the government formalizes its aim to achieving autonomy in producing 
strategic drugs via partnerships for productive development (PDP). More recently, 
public consultation #8 was opened in August/2014 with the content of the bill which 
aims to set criteria and guidelines for the PDPs. cOnclusiOns: For the last 10 years 
the Brazilian government has consistently put in place either legislation or initiates 
to achieve autonomy in producing key products for the public healthcare system.
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be seen as blocking access. As the marginal cost (MC) of a new product is lower than 
the charged price there is a well-known waste. One option is to establish a two-part 
pricing model with a “subscription” price plus a usage price close to MC. The objec-
tive of this paper is to provide an economic analysis based on theories and concepts 
from microeconomics and industrial organization of two-part pricing in the market 
for patent protected medicines (PPM). MethOds: The situation will be analyzed from 
a game theoretical and an empirical perspective. The starting point is the Swedish 
Health Care system with focus on oncology. A two-part pricing contractual arrange-
ment will also be discussed for some other EU countries. Results: Demand side 
consists of a publicly funded local buyer who represents a large number of potential 
users. This often leads to a bargaining solution where price is below the one set by a 
standard monopoly. A two-part pricing - where the buyer pays a substantial fixed-fee 
to get access to the PPM and a per unit price equal to marginal cost – may increase 
efficiency. However, numerous issues need to be taken into account when consider-
ing introducing two-part pricing, for example uncertainty and risk, the operation on 
many markets, free-riders and reselling. cOnclusiOns: Quantities are unlikely to 
be efficient with the current pricing model in the Swedish oncological market. A two-
part pricing is likely to increase the efficiency in such markets but is also associated 
with some serious challenges.
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Objective: To introduce the development of Chinese pediatric medicine, and based 
on foreign experiences propose some measures that China should take immediately 
for improving the access to pediatric medicine and promote Chinese innovation 
for pediatric medicine. MethOds: Data were mainly obtained from the National 
Bureau of Statistics of China, the open Chinese government documents and some 
published papers. Apply descriptive statistics and comparison to summarize poli-
cies’ lacks and propose some suggestions. Results: In 2013, there are 220 million 
Children under 14 years old who account for 16.4% of total Chinese population. In 
the 2009 National Reimbursement Drug List, the number of pediatric medicines 
is about 60 and accounts for 1.52% in all 3500 drugs, 80% of which does not have 
usage information of “exclusive pediatric medicine”, 90% of which does not have 
pediatric formulation. Adverse reaction rate of pediatric medicine is 12.9%, which is 
obviously higher than adult medicine. cOnclusiOns: China should immediately 
take some incentive measures to encourage the innovation of pediatric medicines 
based on foreign experiences
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Incorporating the patient perspective on the value of medicines into health tech-
nology assessments (HTA) is becoming increasingly important as acknowledged 
by several prominent HTA agencies. NICE (UK) has employed several measures, 
including a Citizen’s Council. Canada, particularly in the area of oncology, has a 
formalized process through which patient input on drug reviews and feedback 
on recommendations is obtained to ensure patients’ experiences (both good and 
bad) of living with cancer and undergoing treatment are routinely considered. 
In Australia, there is a consumer representative on the Pharmaceutical Benefits 
Advisory Committee (PBAC) and patients have the opportunity to provide written 
input during the assessment process, although the process of how PBAC consider 
and incorporate this information into their decision is not transparent. There is a 
need for a more formalized framework for eliciting meaningful patient input and 
a more transparent process for how that input is incorporated into the decision 
making process. This research seeks to outline a novel methodological approach 
to elicit and quantify patient values in a systematic way for the purpose of treat-
ment evaluation (Patient Value Mapping). The focus of this research is Chronic 
Lymphocytic Leukemia (CLL) and involves patient participation in multiple research 
stages. Stage 1 involves conducting exploratory qualitative interviews and semi-
structured quantitative surveys to gauge how patients view treatments and what 
outcomes are most important to them. Stage 2 quantifies the insights from stage 
1 using discrete choice based methods, including measuring the relative weight-
ings of importance on each of the outcomes and the associated willingness to pay. 
Current and proposed treatments are entered into the resulting model and scored 
based on how well they align with patient values and expectations. The results of 
this analysis could be incorporated into the HTA evaluation process and used to 
guide decisions around the value of new medicines.
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Objectives: Traditionally, business-related projects are either executed by employ-
ees within an organization or outsourced to external vendors. Crowdsourcing, on 
the other hand, allows sponsors to leverage the Internet to draw upon the skills 
and experiences of the public in open forums to generate new ideas or deliverables. 
Crowdsourcing for healthcare technology innovation has become increasingly popu-
lar; however, the type of stakeholders involved and healthcare technologies sought 
are not well understood. The aim of this study is to characterize crowdsourcing 
competitions focused on healthcare technology innovation. MethOds: Information 
was gathered from the Health 2.0 Developer Challenge website, a leading online 
competition platform where complex healthcare challenges are crowdsourced by 
sponsoring agencies to teams of developers. Completed challenges listed on the 
platform from January 2007-October 2014 were identified. For each challenge, total 
prize money, stakeholder type, and challenge theme were examined. Results: 
A total of 57 challenges were identified with $3.31 million awarded as total prize 
money (mean= $75,250; median= $40,000; max= $750,000). Government agencies 
sponsored the majority of challenges (46%), followed by non-profit (37%) and 
for-profit (25%) organizations. Four (7%) challenges were sponsored by pharma-
ceutical companies and accounted for 14% of total prize money (mean= $117,500; 
median= $150,000; max= $160,000). The five most common challenge themes iden-
tified were data management (25%), enhanced decision making (16%), communi-
cation barrier (14%), health education (14%), wellness/tracking (11%), and disease 
prevention/screening (11%). cOnclusiOns: Although government agencies were 
the most common sponsors of crowdsourced healthcare technology challenges, 
pharmaceutical companies offered the highest mean monetary awards. Data man-
agement solutions (e.g. electronic health record applications) were the most fre-
quently solicited theme among all challenges. Crowdsourcing shows promise as a 
source of innovative healthcare technology solutions; however, more research is 
needed to explore the viability of such solutions.
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Objectives: MCDA provide innovative approaches to measure the value of inter-
ventions and support decision making. A broad range of criteria are used to integrate 
big data and reflect the various constraints under which healthcare decisions are 
made. The objective of this study was to analyze the ethical theories and principles 
embedded in the criteria of holistic MCDA. MethOds: EVIDEM was selected as a 
holistic framework aiming at defining value, or goodness, of healthcare interven-
tions, in its widest sense (axiology), i.e., encompassing their effects on health of 
patients, populations and healthcare systems. Each criterion of the framework was 
analyzed regarding its ethical background theories, inherent norms, values, and 
associated principles, and ethical implications. A broad range of ethical theories and 
positions were considered including virtue ethics, deontology, consequentialism, 
utilitarianism, theory of justice, human rights, and principlism. Results: Criteria 
related to healthcare intervention outcomes (“Effectiveness”, “Safety”, “Patient-
reported outcomes”, Type of benefit) are expressed in the Hippocratic Oath and 
rooted in deontology (imperative to help), principlism (autonomy, beneficence, non-
maleficence), and also in consequentialism. “Disease severity“, “Unmet needs” and 
“Priorities” are related to the theory of justice to prioritize those who are worst 
off, but also to deontology and virtue ethics. “Size of population” is rooted in utili-
tarianism pursuing the greatest good for the greatest number. Economic criteria 
as an inherent part of value appraisal ensure wise use of resources (virtue ethics 
[practical wisdom]) to maximize health under limited resources based on social 
responsibility (utilitarianism). “Affordability and Opportunity costs” and “System 
capacity and appropriate use” are related to consequentialism while “Political/his-
torical/cultural” and “Stakeholders pressure/barriers” are rooted in virtue ethics and 
human rights. cOnclusiOn: Holistic MCDA systematically incorporates a broad 
range of ethical perspectives, norms, values and principles, and as such is a norma-
tive approach for prioritizing healthcare interventions that optimize patients’ and 
healthcare systems health.
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Objectives: Electronic Healthcare databases and use of machine learning algo-
rithms has created opportunities for rapid learning. However, the indiscriminate 
application of machine learning algorithms to non-experimental healthcare 
databases may result in incorrect inferences about possible treatment benefits. 
This paper compares results from large healthcare databases produced by sta-
tistical, machine learning, and hybrid methods to emphasize the importance 
of controlling for known biases in healthcare databases and machine learning 
algorithms. MethOds: MS patient cases were selected from an EMR database 
that met the following criteria: Must be on an MS therapy for at least one year 
and diagnosed with at least one co morbidity prior to and during the treatment 
period. Co morbidity improvements are measured by changes in specific lab val-
ues measured prior to and during treatment. To facilitate method comparison, a 
binary variable was constructed to measure improvements in co morbidities expe-
rienced during MS therapy. Treatment groups were defined by specific MS thera-
pies and compared to control groups treated with alternative therapies during 
the observation period. Propensity scores were used with all methods. Statistical 
and machine learning algorithms were compared to a hybrid algorithm, SIDES, 
originally designed for subpopulation analysis in RCT’s while controlling for multi-
plicity bias (Lipkovich et al. 2011). Results: Initial analyses identified differences 
in predictors of co mobidity improvements. The presentation will cover specific 
comparisons between different methods, highlight similarities and differences 
in findings and provide rationales for divergent results. cOnclusiOn: Machine 
learning methods (such as SIDES) designed for use in RCTs can be adapted for use 
with large healthcare databases to accelerate learning and discovery while also 
including protections against known sources of bias in healthcare data (treat-
ment selection) and machine learning methods (multiplicity) that can lead to 
incorrect inferences.
